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Background: Despite its recent FDA approval, recent analyses of dronedarone provide conflicting views of the efficacy and safety of this 
medication in its use for treatment of atrial fibrillation.
Methods: We sought to perform a random-effects Bayesian meta-analysis and examination the net clinical benefit of the safety and effectiveness 
of dronedarone when compared to placebo. We reviewed efficacy data from 4 trials, and safety data from 8 trials, for a total of 4812 and 6771 
patients respectively. Aggregate Bayesian analysis was performed using 3 models via MCMC methods. Posterior probabilities and sensitivity analysis 
was performed using a step-wise Bayesian approach. Net clinical benefit was derived from efficacy of rhythm recurrence and overall mortality plus 
cardiovascular hospitalization.
Results: Dronedarone was found to have an overall probability of benefit of 99.9%, with a probability of greater than 20% benefit of 99.9%, and a 
probability of greater than 50% benefit of 81.4%. Overall mortality plus cardiovascular hospitalizations were improved by dronedarone, with a 99% 
probability of benefit, and a probability of greater than 20% benefit of 91.5%. Net clinical benefit as determined by Bayesian analysis was 99.9% 
probability of benefit. Limited trials explored other safety measures, and analysis of adverse events requiring discontinuation of an agent favored 
placebo, with a probability of benefit less than 1%.
Conclusions: While controversy exists surrounding the role of dronedarone in management of atrial fibrillation, this analysis confirms the efficacy, 
safety, and net clinical benefit of dronedarone. Further, dronedarone remains an attractive option versus amiodarone, and the specific advantages 
between these two medications warrant further investigation.
